Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

A. Xiong, N. Yang,X. Dong, Y. Fan, L. Xu,P. Pan,Y. Yu, J. Zhou, Y. Li,J. Cui, M. Wang, Y. Zhang, R. Chen, H. Niu, H. Qin, S. Guo,D. Huang, H. Wu,W. Yao, Z. Zhang, J. Fang, Y. Fang, M. Li, L. Liu,W. Su, Z. Wu, X. Wang, H. Liu, J. Hu, X. Xiang, C. Zhou

JOURNAL OF THORACIC ONCOLOGY（2024）

Cited 0|Views2

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined